Earnings Releases·Oct 29, 2026, 4:05 PM ET

ResMed Inc. — First Quarter Fiscal Year 2027 Earnings Summary

Revenue grew 6% year-over-year to $1.415 billion (7% core constant currency), while GAAP diluted EPS rose 23% to $2.92 and non-GAAP diluted EPS increased 14% to $2.91.
Fiscal Year 2027 guidance remains unchanged, projecting revenue of $5.75–$5.85 billion and non-GAAP diluted EPS of $12.00–$12.25.
The company closed the MatrixCare divestiture, reducing debt by approximately $240 million combined across short-term and long-term categories, and returned over $1.0 billion to shareholders via repurchases and dividends.
Strategic initiatives included the U.S. launch of the AirTouch F40 mask, a partnership with Eight Sleep for technology integration, and the appointment of Carol Burt as Lead Director.